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(both miR-675-5p and miR-675-3p) expression in clinical samples.
MiR-675-5p was undetectable in TCGA samples, while miR-675-3p ex-
pression correlated with H19 levels, but was no predictor either for
overall or disease-free survival. At least in their model system that
Calin and coworkers used, H19 effect could hardly be attributed to
miR-675 function (Ohtsuka et al., 2016–in this issue).Numerous studies have reported H19, the ﬁrst discovered long non-
coding RNA (lncRNA), to have key regulatory functions in tumor devel-
opment and progression (Brannan et al., 1990). This paternally
imprinted gene is located close to the telomeric region of chromosome
11p15.5 that frequently harbors genetic alterations in tumors. The activ-
ities of H19 are diverse, and include genetic and epigeneticmechanisms.
Despite the recent disputes and discrepancies showing the involvement
of H19 in opposed processes, e.g., in cell proliferation and differentiation
processes, as well as in epithelial to mesenchymal transition (EMT) and
mesenchymal to epithelial transition (MET), emerging evidence sup-
ports its oncogenic properties (Raveh et al., 2015). The association of
H19 with tumorigenesis and invasion is partially owed to its regulation
of carcinogenic miR-675. H19 is the precursor-RNA of this microRNA
(miRNA) that is located in the ﬁrst exon of the H19 gene (Tsang et al.,
2010). It is actually demanding to ascribe the oncogenic functions of
both molecules either to H19 or to miR-625. Tsang et al. showed that
both, H19 and miR-675 were upregulated in human colorectal cancer
(CRC) cell lines and primary tissues, but H19-derived miR-675 regulat-
ed CRC development by downregulating the tumor suppressor retino-
blastoma 1 (RB1). The fact that RB1 is a direct target of miR-675 was
demonstrated using a luciferase assay; miR-675 suppressed the activity
of the reporter plasmid carrying the 3′-untranslated region (3′UTR) of
RB1 mRNA with the miR-675 binding site (Tsang et al., 2010). In this
case, the data emphasize that H19 functions are performed by miR-
675. However, Calin and coworkers (Ohtsuka et al., 2016–in this
issue) found a direct interaction of H19, without the involvement of
miR-675, with RB1 protein, using RNA immunoprecipitation experi-
ments. This excellent study also showed that H19 silencing dramatically
reduced RB1 phosphorylation by reducing both RNA and protein ex-
pression of cyclin-dependent kinase (CDK) 4 and cyclin D1 (two essen-
tial upstream factors controlling RB1 phosphorylation). Thus, their
ﬁndings indicate that H19 regulates G1-S transition in RB1/E2Fom.2016.10.026.
. This is an open access article undersignaling to control cell proliferation. They also investigated miR-675
Moreover, Calin and coworkers also showed that H19 is able to reg-
ulate β-catenin activity viamodulating CDK8 expression (Ohtsuka et al.,
2016–in this issue). In CRC, CDK8 is an essential oncogenic driver with
multiple functions. Together with its partners cyclin C, MED12, and
MED13, CDK8 forms a subcomplex that controls mediator-polymerase
II interaction to initiate gene transcription (Allen and Taatjes, 2015).
Thus, as a part of the transcription machinery, CDK8 plays a crucial
role in regulating gene expression. Accordingly, the ﬁndings by Calin
and coworkers (Ohtsuka et al., 2016–in this issue) show, that apart
from the detection of the H19 action on CDK8/β-catenin, as well as on
RB1/E2F signaling, H19 may be involved in further regulation networks
that control CRC malignancies.
Compared to previous studies (Raveh et al., 2015), the strength of
the study by Calin and coworkers lies in the detailed investigation on
the involvement of H19 in RB1/E2F and CDK8/β-catenin signaling path-
ways using effectively combined bioinformatics (TCGA database) and in
vitro experimental models (Ohtsuka et al., 2016–in this issue). It is also
of note that H19 was reported to affect the Wnt/β-catenin signaling
pathway (Wang et al., 2016), and additionally, to be involved in the re-
pression of E-Cadherin (CDH1) (Luo et al., 2013). In this regard Luo et al.
demonstrated that H19 repressed CDH1 expression via interactionwith
the member of the polycomb group of proteins EZH2 in bladder cancer
(Luo et al., 2013), whereas Calin and coworkers suggested another
mechanism in CRC by revealing that CDH1 as well as CSRP2 are direct
H19 targets, and thus, identiﬁed H19 as themost signiﬁcant lncRNA as-
sociated with CRC patient survival (Ohtsuka et al., 2016–in this issue).
In recent years, elucidating the role of lncRNAs in tumors has be-
come a hot research topic. Their potential applications in the clinical di-
agnosis and treatment of cancer are promising. Knowledge of aberrant
signal transduction pathways underlying tumor progression,metastasis
and drug resistance have provoked development of targeted therapies
which inhibit oncogenic signals. However, the potential mechanisms
of how lncRNAs affect signaling pathways remain largely undeﬁned,
and most of lncRNA functions remain unclear. The excellent study by
Calin and coworkers (Ohtsuka et al., 2016–in this issue) may contribute
to advancing our knowledge on lncRNAs, in particular for H19 in CRC. Inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of cell-cycle genes and signaling pathways (Raveh et al., 2015; Ohtsuka
et al., 2016–in this issue; Han et al., 2016), H19 should be considered
more profoundly as a therapeutic target and a cancer marker in the
ﬁght against cancer. Accordingly, the detailed investigations by Calin
and coworkers could help H19 to become a targetedmolecule for preci-
sion and personalized medicine. To achieve a more effective antitumor
therapeutic approach, future lncRNA-based methods are anticipated to
improve the treatment and prognosis of CRC. However, it should be
kept in mind that a signaling pathway can be affected by several
lncRNAs ormiRNAs, and that a single lncRNA andmiRNA can affect sev-
eral pathways. Thus, it is possible that silencing of only H19 cannot stop
CRC tumorigenesis and progression. Therefore, prior to starting targeted
therapy with lncRNAs, their multiple behaviors should be investigated.
Their expression patterns in the temporal and local context also need
to be taken into contextual evaluation. Finally, the recent doubts on
the oncogenic properties of H19 should be eliminated, to deﬁnitely
demonstrate whether H19 as targeted molecules may be beneﬁcial in
CRC patients.
Besides, increasing evidence has indicated that lncRNAs andmiRNAs
can regulate each other and affect their activity and function. On the one
hand, lncRNAs may be the precursor of miRNAs, whereas on the other
hand, lncRNAs may be the targets of miRNAs. Accordingly, Salmena et
al. (2011) introduced the competing endogenous RNA (ceRNA) hypoth-
esis, and suggested that miRNA response elements (MREs) can build a
bridge for the communication among various types of RNAs. Acting as
ceRNAs, lncRNAs may regulate posttranscriptionally the levels of
miRNA targets. Notably, an example for these cross talks between
lncRNAs and miRNAs is H19 and miR-675, that interaction should fur-
ther be analyzed.
So far, H19has not beenmeasured in the blood circulation of CRC pa-
tients. To date, quantiﬁcations of circulating H19 have been carried par-
ticularly in plasma of gastric and breast cancer patients, and its role as a
potential non-invasive diagnostic biomarker has been demonstrated in
both cancer types (Hashad et al., 2016; Zhang et al., 2016). Considering
that during chemotherapy no or little tumor tissue is available, the pos-
sibility of monitoring the changes in circulating nucleic acid proﬁles in-
duced by treatment becomes increasingly important. Therefore, it
would also be interesting to perform such non-invasive analyses in
CRC patients and to examinewhether plasmaH19 can serve as a poten-
tial “liquid biopsy” biomarker for CRC diagnosis or prognosis. Addition-
ally, the quantiﬁcation of H19 levels in the blood circulation of CRCpatients could also help to monitor their response to therapy, and iden-
tify those patients who can beneﬁt from adjuvant chemotherapy.
In conclusion, Calin and coworkers (Ohtsuka et al., 2016–in this
issue) have impressively analyzed anddescribed the complexmolecular
mechanisms of H19 in CRC. Although the diverse functions of H19 need
to be further clariﬁed, as well as its downstream targets, the role of H19
in RB1/E2F and CDK8/β-catenin signalingmay not only help us to eluci-
date the pathogenesis of CRC, but also offer H19 as promising target
molecule for lncRNA-based clinical strategies.Disclosure
The author declares no conﬂict of interest.References
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